Table 4.
Outcome | Weighted Average |
---|---|
Partial tumor response | 40% |
Stable disease | 50% |
Progressive disease | 10% |
Hearing improvement | 36% |
Stable hearing | 46% |
Hearing Loss | 18% |
Severe adverse effects (Grade 3/4) | 13% |
Other adverse effects | 69% |
No adverse effects | 18% |